
Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

Your AI-Trained Oncology Knowledge Connection!


Alireza Ghoreifi, MD, Duke University Department of Urology, and member of the Society of Urologic Oncology (SUO) Fellow.

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.